<DOC>
	<DOCNO>NCT01475383</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy investigational compound designate PF-03654746 compare placebo treatment adult Tourette 's Syndrome . The study also explore pharmacokinetics PF-03654746 adult Tourette 's Syndrome .</brief_summary>
	<brief_title>Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette 's Syndrome</brief_title>
	<detailed_description>The study terminate 11-Apr-2012 due internal reassessment priority sponsor . The decision terminate base safety efficacy concern .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Tourette Syndrome</mesh_term>
	<criteria>Primary diagnosis Tourette 's Syndrome Englishspeaking male female adult 18 55 year age generally good health . Free medication treat tic least 6 week prior randomization . Females childbearing potential must use medically acceptable birth control duration study 28 day study participation . Tic treatment include protocolspecified drug , train ticsuppressing behavioral technique , habit reversal training use Onabotulinum toxin A injection . History neurologic evidence secondary tic disorder , psychosis , bipolar disorder , tardive dyskinesia , untreated unstable DSMIV Axis I disorder require treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Tourette 's Syndrome adult</keyword>
	<keyword>Safety Efficacy</keyword>
	<keyword>Randomized</keyword>
	<keyword>Placebo Control</keyword>
	<keyword>Cross-over</keyword>
</DOC>